Business
Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives
Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This proof-of-concept data supported the initial clinical development of brilaroxazine and reinforces the clinical profile demonstrated in the Phase 2 REFRESH trial Topline data from Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 CUPERTINO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented the foundational preclinical data that supported the initial clinical development of its novel serotonin-dopamine stabilizer brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) in San Diego. The Company also announced acceptance of this data for publication in Medical Research Archives. The SOBP poster and online publication will be available at revivapharma.com/publications. “We were pleased to present at SOBP and simultaneously publish in Medical Research Archives these foundational preclinical data highlighting the antipsychotic effects of brilaroxazine on pharmacologic-induced behaviors associated with psychosis and schizophrenia in translational animal models,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. “Building on the proof-of-concept data that supported the clinical development of brilaroxazine, these data reinforce the favorable clinical profile seen following dopamine and serotonin pathway modulation in our Phase 2 REFRESH trial in schizophrenia. We believe the multifaceted activity of brilaroxazine is the basis for this significant impact on behavioral symptoms and accompanying neuroinflammation, differentiating brilaroxazine as a next-generation treatment for conditions driven by dysfunctional dopamine and serotonin signaling. We look forward to topline data from our Phase 3 RECOVER trial expected in mid-2023.” Schizophrenia is accompanied by a complex mix of positive, negative, and mood symptoms, cognitive impairment, and immune system abnormalities associated with dysfunctional dopamine and serotonin signaling. Limitations o...